ixekizumab injection
for subcutaneous use Initial U.S. Approval: 2016

ixekizumab injection is a humanized interleukin-17A antagonist indicated for the treatment of: • patients aged 6 years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. • adults with active psoriatic arthritis. • adults with active ankylosing spondylitis. • adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation.

Facts about ixekizumab injection

DISEASE INDICATIONS-Psoriasis
MANUFACTURER-Eli Lilly Nederland B.V.
USAGE-Subcutaneous
MEDICINE APPROVED BY-European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import ixekizumab injection” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.